Challenging the dogma: a randomized trial of standard vs. half-dose concomitant nonbismuth quadruple therapy for Helicobacter pylori infection

BACKGROUND: Current treatment of Helicobacter pylori consists of three or four drugs for 7–14 days with important associated cost and adverse events. AIMS: This study compared efficacy and safety of standard dose vs. half-dose concomitant nonbismuth quadruple therapy (NBQT) for 7 days. The standard...

Descripción completa

Guardado en:
Detalles Bibliográficos
Autores principales: Sharara, Ala I, Sarkis, Fayez S, El-Halabi, Mustapha M, Malli, Ahmad, Mansour, Nabil M, Azar, Cecilio, Eloubeidi, Mohamad A, Mourad, Fadi H, Barada, Kassem, Sukkarieh, Ismail
Formato: Artigo
Lenguaje:Inglês
Publicado: SAGE Publications 2014
Materias:
Original Articles
Acceso en línea:https://ncbi.nlm.nih.gov/pmc/articles/PMC4212457/
https://ncbi.nlm.nih.gov/pubmed/25360301
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1177/2050640614530919
Etiquetas: Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!

Ejemplares similares